Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3011 in malignant ascites from colorectal cancer
NCT06200376Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVR-T3011 in malignant ascites and colorectal cancer (CRC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Adverse event. Started Sep 2023; status: recruiting.
02
Drugs
MVR-T3011
03
Conditions
malignant ascitescolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06200376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06200376.